| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer
|
Chen B.-B.; Lu Y.-S.; Yu C.-W.; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C.; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; ANN-LII CHENG; Tzen K.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
|
Chen K.-H.; Lin L.-I.; Tseng L.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:24Z |
Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Wu M.-S.; Yeh K.-H.; Lin C.-W.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness
|
Hsu C.-Y.; Wang C.-W.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
|
Price T.; Shen L.; Ma B.; Esser R.; Chen W.; Gibbs P.; Lim R.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
The APPLE Association Predident's Message
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)
|
Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma
|
Shao Y.-Y.; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
|
Chen Y.-H.; Wang C.-W.; Wei M.-F.; Tzeng Y.-S.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; Huang C.-S.; ANN-LII CHENG; Lu Y.-S.; Asian Breast Cancer Cooperative Group |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations
|
Chen C.-H.; Lu Y.-S.; ANN-LII CHENG; Huang C.-S.; Kuo W.-H.; Wang M.-Y.; Chao M.; Chen I.-C.; Kuo C.-W.; Lu T.-P.; Lin C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma
|
Shen Y.-C.; Hsu C.-L.; Jeng Y.-M.; Ho M.-C.; Ho C.-M.; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; Hu R.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Milestones in the pathogenesis and management of primary liver cancer
|
Nault J.-C.; ANN-LII CHENG; Sangro B.; Llovet J.M. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial
|
Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
|
Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG; IMbrave150 Investigators |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
|
Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
|
Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:17Z |
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
|
Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
|
Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue
|
Tsai H.-J.; Tai J.J.; Chen L.-T.; Wu M.-S.; Yeh K.-H.; Lin C.-W.; Wang T.-E.; Wang H.-P.; Yu F.-J.; Liou J.-M.; Hsiao C.-F.; Cheng T.-Y.; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; Shun C.-T.; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; Lu Y.-S.; Huang C.-S.; ANN-LII CHENG; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply
|
Finn R.S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
|
Kasper S.; Foch C.; Messinger D.; Esser R.; Lamy F.-X.; Rothe V.; Chen W.; ANN-LII CHENG; Rouyer M.; Brodowicz T.; Zielinski C. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|
Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas
|
Ma W.-L.; Yeh K.-H.; Yao M.; Tang J.-L.; Lin C.-W.; Wang Y.-T.; Yeh Y.-C.; Wang H.-P.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
|
Ryoo B.-Y.; ANN-LII CHENG; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240
|
Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
Pursuing efficacious systemic therapy for hepatocellular carcinoma
|
ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:13Z |
An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
|
Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
